Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.49 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | TTK | P33981 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2689845 | 0.84 | CYP2A6 (0.54) | CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL11257993 | 0.83 | CA12 (0.57) | CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL11232120 | 0.83 | AURKB (0.55) | CYP2C9CYP2C19CA12CA1CA2 | |
| SCHEMBL4059984 | 0.81 | TBXAS1 (0.56) | CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL11233206 | 0.79 | CYP11B2 (0.45) | CYP2A6AURKATTKAURKBINCENP | |
| SCHEMBL4061767 | 0.78 | CYP2A6 (0.50) | CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL12279439 | 0.78 | CYP2A6 (0.54) | CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL12744778 | 0.76 | CYP2A6 (0.53) | CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL28574445 | 0.76 | CYP2A6 (0.53) | CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL11242510 | 0.74 | CCNC (0.38) | CYP2A6CYP2E1CYP2C9CYP2B6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511038-B2 | Pyridazin-3(2H)-one derivatives and their use as PDE4 inhibitors | LABORATORIOS ALMIRALL S.A. (ES) | 2009-03-31 | — | — | US | disclosed |
| US-20070197536-A1 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-08-23 | — | — | US | disclosed |
| CN-1878759-A | Pyridazin-3 (2H) -one derivatives and their use as PDE4 inhibitors | ALMIRALL PRODESFARMA SA (ES) | 2006-12-13 | — | — | CN | disclosed |
| EP-1682519-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | Almirall Prodesfarma, S.A. (ES) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005049581-A1 | PYRIDAZIN-3 (2H) -ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | ALMIRALL PRODESFARMA, S.A. (ES) | 2005-06-02 | — | — | WO | disclosed |
| US-4346221-A | Preparation of 4-amino-6-(pyridinyl)-3(2H)-pyridazinones from 6-(pyridinyl)-3(2H)-pyridazinones | STERLING DRUG INC. (US) | 1982-08-24 | — | — | US | disclosed |
| US-4338446-A | Di-(lower-alkyl)hydroxy-[2-oxo-2-(pyridinyl)ethyl]-propanedioates | STERLING DRUG INC. (US) | 1982-07-06 | — | — | US | disclosed |
| US-4305943-A | 4-Amino-6-(pyridinyl)-3(2H)-pyridazinones and their use as cardiotonics | STERLING DRUG INC. (US) | 1981-12-15 | — | — | US | disclosed |
| US-4304776-A | 4-Substituted-6-(pyridinyl)-3(2h)-pyridazinones and their use as intermediates and cardiotonics | STERLING DRUG INC. (US) | 1981-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197536-A1 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | PDE12, PDE4A, PDE7A | CYP2A6 137/4885CYP2E1 55/4885CYP2C9 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.